If the market for our product candidates, or our share of that market, is not as large as we expect, the number of indications approved by regulatory authorities is narrower than we expect or the target population for treatment is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such products to become profitable. If we are unable to successfully complete development and obtain regulatory approval for our lead product candidates, namely ONS-3010, ONS-1045 and ONS-1050, our business will be harmed.
We will need to raise substantial additional funding to complete the expansion of our manufacturing plant and development of our product candidate pipeline. This additional funding may not be available on acceptable terms or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our contract development and manufacturing and/or product development efforts or other operations.
Our plans to expand our manufacturing facility to support our efforts to begin selling contract development and manufacturing services will require significant additional funding to complete the expansion. We are also currently advancing our product candidates through preclinical development, but have decided to secure additional development partners before advancing our product candidates into and through clinical trials. Developing product candidates is an expensive, risky and lengthy process, and upon securing additional development partners we expect our expenses to increase in connection with our ongoing activities, particularly as we continue the research and development of, continue and initiate clinical trials of, and seek marketing approval for, our product candidates, in particular ONS-3010 and ONS-1045.

### Language ###
English

### Assessment ###
A user might want to know what specific products are being developed by this company.

### Query ###
What are the main product candidates being developed by ONS?
What are the main product candidates being developed by ONS?